Immunic Inc. (NASDAQ: IMUX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT IMMUNIC INC.

Immunic Inc. (NASDAQ: IMUX)
Listen to this Section


$15.16
+0.0940 ( +0.62% ) 153.5K

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Clinical Trial Pipeline Stages


Drug Name Stage
Vidofludimus calcium (IMU-838)DetailsMultiple sclerosis, Autoimmune disease Phase 2
Vidofludimus calcium (IMU-838)DetailsBowel disorder, Inflammatory bowel disease, Ulcerative colitis Phase 2b
IMU-856DetailsCeliac disease Phase 2b
Vidofludimus calcium (IMU-838)DetailsCOVID-19, Infectious disease Phase 2
Vidofludimus calcium (IMU-838)DetailsPrimary sclerosing cholangitis, Bile duct disease, Liver disease Failed
Izumerogant (IMU-935)DetailsPsoriasis Failed

Market Data


Open $15.16
Previous Close $15.07
Volume 153.5K
Market Cap $200.37M
Day Range $14.72 - $15.67
52 Week Range $5.06 - $15.77
Shares Outstanding 13.62M
Change % +0.62%
Net Change ▲ 0.0940
Insider Ownership -0.18%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2014
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -3,093,804.00

Date Type Amount Purchased Purchaser
2024-03-06 Sale -19973.00 PHILLIPS BARCLAY A
2024-03-06 Sale -9986.00 Nash Duane
2024-02-28 Buy 14000.00 Vitt Daniel
2024-01-19 Sale -300000.00 Nash Duane
2024-01-19 Sale -1160000.00 Vitt Daniel
2024-01-19 Sale -335400.00 Muehler Andreas
2024-01-19 Sale -295400.00 Whaley Glenn

SEC Filings


Form Type Description Pages Date
schedule Other 3 Nov 14, 2025
schedule Other 1 Nov 14, 2025
10-q Quarterly Reports 95 Nov 13, 2025
8-k 8K-related 14 Nov 13, 2025
8-k 8K-related 28 Sep 25, 2025
8-k 8K-related 87 Aug 07, 2025
10-q Quarterly Reports 94 Aug 07, 2025
4 Insider transactions 1 Jul 18, 2025
4 Insider transactions 1 Jul 18, 2025
4 Insider transactions 1 Jul 18, 2025

Latest News